Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to...
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry,...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...
Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting con...
Revvity (NYSE:RVTY) reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
What Happened? Shares of life sciences company Revvity (NYSE:RVTY) jumped 3.1% in the afternoon session after the company reported strong second-quarter 2026...
Life sciences company Revvity (NYSE:RVTY) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.5% year on year to $711.1 millio...
Revvity (NYSE:RVTY) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data.
Life sciences company Revvity (NYSE:RVTY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.2% year on year to $729.7 mil...
Life sciences company Revvity (NYSE:RVTY) will be reporting earnings this Tuesday before the bell. Here’s what investors should know. Revvity missed analysts...
